Profile
Max W.
Talbott worked as SVP-Worldwide Commercial Development at Introgen Therapeutics, Inc. from 2002 to 2008.
Prior to that, he was SVP-Drug Regulatory Affairs & Quality Assurance at Aventis Pharmaceuticals, Inc. from 1996 to 2000, and Senior Vice President-Worldwide Regulatory Affairs at DuPont Pharmaceuticals Co. from 2000 to 2002.
He also held the position of Vice President-Regulatory Affairs at Multivir, Inc. Talbott received his undergraduate and graduate degrees from Ball State University (Indiana) and his doctorate from Rutgers State University of New Jersey.
Former positions of Max W. Talbott
Companies | Position | End |
---|---|---|
INTROGEN THERPUT | Chief Tech/Sci/R&D Officer | - |
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | General Counsel | 2001-12-31 |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Corporate Officer/Principal | 1999-12-31 |
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | General Counsel | - |
Training of Max W. Talbott
Ball State University (Indiana) | Graduate Degree |
Rutgers State University of New Jersey | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. Medical SpecialtiesHealth Technology Introgen Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company develops molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. The company maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. It was founded in June 1993 and is headquartered in Austin, TX. | Health Technology |
DuPont Pharmaceuticals Co.
DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
Aventis Pharmaceuticals, Inc.
Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Multivir, Inc.
Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
- Stock Market
- Insiders
- Max W. Talbott